Apolipoprotein B in cardiovascular risk assessment
Date Added:
October 2, 2023
Journal/Publication:
CMAJ
Publisher:
CMA
Publication Date:
August 28, 2023
Issue:
33
Volume:
195
Type:
Meta-analyses, Reviews, and Guidelines
Format:
Article
DOI (1):
10.1503/cmaj.230048
PMID (1):
37640407
Abstract
Apolipoprotein (apo) B measurement is a recommended alternative to low-density lipoprotein cholesterol (LDL-C)
The 2021 Canadian Cardiovascular Society guideline on dyslipidemia recommends that physicians may use levels of either non-high-density lipoprotein cholesterol (HDL-C) or apo B instead of LDL-C for screening and targets of treatment.1 Non-HDL-C represents total cholesterol minus cholesterol from HDL particles; apo B represents the total number of atherogenic particles, since 1 apo B molecule is found on each LDL, very low–density lipoprotein, intermediate-density lipoprotein and lipoprotein(a) particle.2
Text Availability
Free full text
RPR Commentary
RPR Commentary: Apo B may be a more accurate and convenient measure of CAD event risk than LDL cholesterol. James W. Mold, MD, MPH